
|Videos|March 14, 2017
Access to High Cost Drugs Remains a Challenge in Specialty
Author(s)Lauren Santye, Assistant Editor
Paul LeVine, vice president of Analytic Services at Trial Card, discusses potential ways to overcome the hurdle of limited access to high cost specialty drugs.
Advertisement
Paul LeVine, vice president of Analytic Services at Trial Card, discusses potential ways to overcome the hurdle of limited access to high cost specialty drugs.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
2
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
3
FDA Approves Targeted Combination Therapy for BRCA2-Mutated Prostate Cancer
4
Targeted ADCs Break Through Barriers in HER2-Positive Breast Cancer
5

















































































































































































































